INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to expand the labeling on the INVOcell device and its indication for use to provide for a 5-day incubation period. The data supporting the expanded 5-day inc...
Next-generation FDA-cleared medical device brings non-invasive heart and lung disease detection to healthcare professionals at the point of care ...
Manipal Hospitals and Queen Elizabeth University Hospital – Interventional Radiology departments ink partnership...
State-of-the-art facility span over 2,32,000 square feet ...
Union Health Minister inaugurates the department...
To build training capacity of eye health professionals in glaucoma...
The joint venture will undertake the training of 100 medical and nursing graduates in a year...
SBI will provide a CSR donation of Rs 24 crore for the establishment of the Orthopaedics Wing...
Launches first comprehensive genome sequencing test with geneticist and medical consultation...
The collaboration will help in strengthening the capacity of the State Government health institutions in paediatric cardiac care ...
![[L-R]: Ms. Vivien Tan, XP Business Manager, Siemens Healthineers ASEAN; Prof. Dr. dr. Lina Choridah, Sp.Rad (K), Chairwoman Indonesian Woman Imaging Society; Hendya Perbangkara, Head of Diagnostic Imaging, Siemens Healthineers Indonesia](/uploads/articles/l_r__ms_vivien_tan_xp_business_manager_siemens_healthineers_asean-24188.jpg)
